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c-IAP1 (cellular inhibitor of apoptosis 1) has recently emerged as
a negative regulator of the non-canonical NF-κB (nuclear factor
κB) signalling cascade. Whereas synthetic IAP inhibitors have
been shown to trigger the autoubiquitination and degradation
of c-IAP1, less is known about the physiological mechanisms
by which c-IAP1 stability is regulated. In the present paper,
we describe two distinct cellular processes that lead to the
targeted loss of c-IAP1. Recruitment of a TRAF2 (tumour
necrosis factor receptor-associated factor 2)–c-IAP1 complex
to the cytoplasmic domain of the Hodgkin’s/anaplastic large-
cell lymphoma-associated receptor, CD30, leads to the targeting
and degradation of the TRAF2–c-IAP1 heterodimer through a
mechanism requiring the RING (really interesting new gene)
domain of TRAF2, but not c-IAP1. In contrast, the induced
autoubiquitination of c-IAP1 by IAP antagonists causes the
selective loss of c-IAP1, but not TRAF2, thereby releasing
TRAF2. Thus c-IAP1 can be targeted for degradation by two
distinct processes, revealing the critical importance of this
molecule as a regulator of numerous intracellular signalling
cascades.
Key words: CD30, inhibitor of apoptosis (IAP), lymphoma,
nuclear factor κB (NF-κB), second mitochondrial-derived
activator of caspase (Smac)/direct inhibitor of apoptosis-binding
protein with low pI (DIABLO), tumour necrosis factor
receptor-associated factor (TRAF).
INTRODUCTION
CD30, a member of the TNFR [TNF (tumour necrosis factor)
receptor] superfamily, has been the subject of much investigation
because of its greatly elevated expression in several types of leuk-
aemia and lymphoma cells, including ALCL (anaplastic large-
cell lymphoma) and HL (Hodgkin’s lymphoma) [1,2]. Normally,
CD30 expression is restricted to a small subset of activated B-
and T-cells, and has been shown to induce downstream signalling
events through TRAFs (TNFR-associated factors), similarly to
othermembersoftheTNFRfamilysuchasTNFR2andCD40[3].
In particular, the activated CD30 receptor leads to the induction
of the NF-κB (nuclear factor κB) transcription factor cascade
through a mechanism that is largely TRAF-dependent [4–7].
Induction of NF-κB-responsive genes is critical for immune
responses, cell survival and proliferation, and the up-regulation
of CD30 in leukaemia and lymphoma cells promote aberrant NF-
κB activation driving lymphomagenesis [8,9]. Two major NF-κB
pathways have been described, both of which are activated
in response to CD30 stimulation [10]. The canonical pathway
involves phosphorylation of IκBα (inhibitor of NF-κB α),
and, in the alternative pathway, p100/NF-κB2 is proteolytically
processed to p52 [11].
IAP (inhibitor of apoptosis) proteins are a broadly expressed
group of intracellular factors that function in a wide range of
cellular processes in addition to their initially described role in
thesuppressionofprogrammedcelldeath[12].Agrowingbodyof
work is revealing alterations in both the expression and activity
of numerous IAP proteins in neoplastic, lymphoproliferative and
metabolicdisorders,althoughgiventhediverserangeoffunctions
attributed to these proteins, the speciﬁc contributions of the IAP
proteins to these disorders are still being elucidated [13–15].
IAP proteins contain one to three tandem repeats of an ∼70
residue BIR (baculoviral IAP repeat) domain [16]. In addition,
several members of the IAP family, including the c-IAP (cellular
IAP) proteins (c-IAP1 and c-IAP2), contain a C-terminal RING
(really interesting new gene) domain that possesses E3 ubiquitin
ligase activity [17,18]. Several IAP proteins have been implicated
in the regulation of cell death through their ability to bind and
enzymatically inhibit certain members of the caspase family,
which are the primary effectors of the apoptotic programme.
However, IAP proteins differ remarkably in their caspase-
inhibiting ability, with XIAP (X-linked IAP) being the best
described caspase inhibitor, whereas c-IAP1 and c-IAP2 can
bind caspases but do not inhibit their enzymatic activity [19,20].
Originally identiﬁed through their association with TNFR2, c-
IAP1 and c-IAP2 are recruited to TNFRs by TRAFs, primarily
TRAF2 [21].
The c-IAP1 and c-IAP2 proteins were originally identiﬁed as
TRAF-associated proteins [21], and c-IAP1 was identiﬁed
in amplicons associated with squamous cell carcinoma and
hepatocellularcarcinoma,inwhichelevatedexpressioncorrelates
withresistancetoradiotherapy[22,23].c-IAP1wasalsoidentiﬁed
as a putative oncogene, functioning synergistically with c-
Myc, in a murine hepatocellular carcinoma genetic screen
[23], and, independently, c-IAP1 was also shown to target
the c-Myc regulatory factor, MAD1 (mitotic arrest-deﬁcient
protein 1), for proteasome-mediated degradation [24]. Thus it
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is now evident that c-IAP1 can function in a range of cellular
processes.
Previous reports have revealed several elegant mechanisms
by which the activity of IAP proteins can be regulated. For
instance, a number of mitochondrial proteins have been identiﬁed
that are released into the cytosol during apoptosis, along with
cytochrome c, which can bind to and antagonize IAP proteins
[12,25]. These proteins share a conserved N-terminal domain
known as the IBM (IAP-binding motif), and this motif has been
shown to play a key role in the association with various IAPs.
The best characterized mammalian IBM-containing protein is
Smac(secondmitochondrial-derivedactivatorofcaspase),known
as DIABLO (direct IAP-binding protein with low pI) in mice.
Although Smac was originally identiﬁed as an XIAP antagonist
[26,27],itisalsoknowntorecognizeotherIAPproteins,including
c-IAP1 [26–28]. Many of the binding properties of Smac can be
recapitulated by a conserved tetrapeptide sequence, and small-
molecule IAP antagonists that mimic the action of Smac have
been designed to potentiate apoptosis in cancer cells [29–32].
Additionally,Smaccanbeselectivelyreleasedfrommitochondria
in the absence of an apoptotic stimulus, and, indeed, in healthy
cells, cytosolic Smac has been described, produced either as an
alternatively spliced variant whose maturation has been shown to
bypass mitochondria or through other less well-deﬁned processes
[33,34].TheseﬁndingssuggestthattheregulationofIAPproteins
may be of central importance in the homoeostatic control of a
number of physiological processes in addition to apoptosis.
In the present study, we examined the functional consequences
reﬂectedbythecellularinteractions betweenc-IAP1,TRAF2and
Smac. We describe two apparently independent mechanisms by
which c-IAP1 can be targeted for degradation. CD30-mediated
cellular activation induces the degradation of a TRAF2–c-IAP1
complex, through a process that requires the RING domain of
TRAF2. In contrast, Smac or a synthetic IAP antagonist triggers
the selective degradation of c-IAP1, but not TRAF2, through the
RING domain of c-IAP1. The consequence of c-IAP1 targeting
by either of these processes is the activation of the non-canonical
NF-κB pathway, consistent with previously proposed mechan-
ismsfortheroleofc-IAP1inthissignallingcascade.SinceNF-κB
activation has frequently been associated with the transcriptional
induction of gene signatures involved in cytoprotection, these
ﬁndings indicate that the c-IAP proteins and IBM-containing
proteins such as Smac can function in pro-apoptotic and anti-
apoptotic signalling pathways.
EXPERIMENTAL
Materials
Reagents were obtained from the following sources: Ni-NTA
(Ni
2+-nitrilotriacetate)–agarose (Invitrogen), DMSO (Sigma–
Aldrich), cell culture media (Mediatech), Ficoll-Paque PLUS
(GE Healthcare) and QuikChange site-directed mutagenesis kit
(Stratagene). AEG40730 was a gift from Aegera Therapeutics.
Antibodies were obtained from the following sources: anti-
TRAF2 (BD Pharmingen), anti-(COX IV) (cytochrome oxidase
subunit IV) (Invitrogen), anti-Smac/DIABLO (Calbiochem),
anti-GST (glutathione transferase) (Santa Cruz Biotechnology),
horseradish-peroxidase-conjugated anti-HA (haemagglutinin),
horseradish-peroxidase-conjugated anti-FLAG, anti-β-actin
(Sigma–Aldrich), anti-p52/p100 (Upstate Biotechnology), and
horseradish-peroxidase-conjugated anti-mouse, anti-rabbit
and anti-rat (GE Healthcare). Anti-c-IAP1 was kindly provided
by Dr John Silke (Department of Biochemistry, La Trobe
University, Melbourne, Victoria, Australia) [35].
Plasmids
pEBB-HA c-IAP1 was subcloned from pEBG c-IAP1 [36]. Site-
directed mutagenesis of c-IAP1 to generate c-IAP1 H588A, a
mutant c-IAP1 deﬁcient in E3 ubiquitin ligase activity, was
performed using the QuikChange site-directed mutagenesis kit.
pEBB-His6-Ub was a gift from Dr Ezra Burstein (University of
Texas Southwestern Medical Centre, Dallas, TX, U.S.A.). Unless
noted otherwise, plasmids used in the present study have been
described previously [37–39].
Cell lines
HEK (human embryonic kidney)-293 cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium, Karpas 299 and L428 cells
wereculturedinRPMI1640medium,andCHO(Chinese-hamster
ovary) cells were cultured in Ham’s F12 nutrient medium. All
media were supplemented with 10% fetal bovine serum and
2m ML-glutamine and maintained at 37◦C in an atmosphere of
95% air and 5% CO2.
Transfections
HEK-293 cells were transfected with plasmids using a standard
calcium phosphate transfection protocol. Both plasmids and
siRNA (short interfering RNA) oligonucleotides were transfected
into Karpas 299 cells using a Bio-Rad Gene Pulser II
electroporator at 300 V and 950 μF.
CD30 stimulation and treatment with AEG40730
Stimulation of Karpas 299 cells with CD30L
+ (CD30 ligand)
CHO cells was performed as described previously [10]. Brieﬂy,
Karpas 299 cells were resuspended in a 1:1 mixture of RPMI
1640 and Ham’s F12 nutrient media at a ﬁnal concentration
of 10
6 cells/ml. CHO cells (negative control) or CD30L
+ CHO
cells were seeded 24 h previously at a density of 0.8×
10
6 cells/well, and 1 ml of Karpas 299 cells were layered on to
CHO cells in six-well plates for 2 h. Karpas 299 cells were then
removed from the CHO cells by gentle pipetting and collected by
centrifugation at 200 g for 5 min. Cells were washed with 1 ml
of PBS, and subsequently centrifuged at 200 g for 5 min, and
resuspended in RIPA lysis buffer (PBS containing 1% Nonidet
P40, 0.5% sodium deoxycholate and 0.1% SDS) supplemented
with protease inhibitors. HEK-293 or Karpas 299 cells were
treated with 0–25 nM AEG40730 for 24 h, or treated for 0–
48 h with 25 nM AEG40730, as described in the Results section.
DMSO was used as a control for all AEG40730 treatments.
Cell lysate preparation and immunoblot analysis
Cell lysates were prepared with RIPA lysis buffer, supplemented
withproteaseinhibitors,for30 minonicetoensurecompletelysis
unless noted otherwise. Protein quantiﬁcation was determined
using a Bradford assay (Bio-Rad Laboratories). RIPA cell lysates
of equal protein concentrations were prepared in LDS (lithium
dodecyl sulfate) sample buffer, separated on denaturing NuPAGE
4–12% polyacrylamide gradient gels, and transferred on to
0.45 μM nitrocellulose membranes (Invitrogen). Membranes
were blocked in 5% (w/v) dried non-fat skimmed milk powder
in TBS (Tris-buffered saline) with 0.02–0.2% Tween 20 (Bio-
Rad Laboratories), depending on the antibody requirements,
followed by incubation with the indicated antibodies in 2.5%
(w/v) dried non-fat skimmed milk powder for 1 h at room
temperature (25◦C) or overnight at 4 ◦C. After washing with TBS
containing 0.02–0.2% Tween 20, membranes were incubated
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with secondary antibodies for 1 h at room temperature. ECL®
(enhanced chemiluminescence) (GE Healthcare) was used to
visualize the blots.
Cellular fractionation preparation
Karpas 299 or L428 cells (10
6 cells/treatment) were prepared
as described previously [40], with minor protocol modiﬁcations.
Cells were harvested, washed with PBS, resuspended at 3×10
7
cells/ml in digitonin extraction buffer (PBS containing 250 mM
sucrose, 70 mM KCl, 1 mM PMSF and 200 μg/ml digitonin)
supplemented with additional protease inhibitors. Following
incubation on ice for 5 min, samples were centrifuged at 1000 g
for 5 min. RIPA lysis buffer was used to lyse sample pellets,
as described above. Supernatants (cytoplasmic extracts) were
collected and centrifuged again at 1000 g f o r5m i nt or e m o v ea n y
residual debris. Extract protein concentrations were normalized
using a Bradford assay.
RNA interference
Cells (10
7 cells/transfection) were transfected with 16 μgo f
siRNA oligonucleotides (Xeragon/Qiagen) by electroporation.
Gene-speciﬁctargetingofSmacwasperformedusingapreviously
described oligonucleotide corresponding to nucleotides 156–
176 of the coding sequence of Smac [38]. As a negative
control, a previously described oligonucleotide corresponding
to nucleotides 322–342 of GFP (green ﬂuorescent protein) was
utilized [38]. At 24 h after electroporation, dead cells were
removed by centrifugation at 400 g for 20 min on a Ficoll-Pique
PLUS density cushion. At 48 h after transfection, CD30 was
stimulated on the transfected cells for 2 h as described above.
Following CD30 stimulation, total RNA was isolated from half
of the cells and subjected to real-time reverse transcription–PCR.
The remaining fraction of cells was used for whole-cell lysate
preparation and Western blot analysis.
Real-time reverse transcription–PCR
Karpas 299 cells were transfected with plasmids or oligo-
nucleotides, stimulated with CD30L for 2 h as described above
and then washed with PBS. Total RNA was isolated using
the RNeasy minikit (Qiagen) according to the manufacturer’s
instructions. Reverse transcription with random hexamer primers
and MultiScribe
TM reverse transcriptase (Applied Biosystems)
was performed on 100 ng of total RNA. The indicated target
assays were performed on 1 μl of cDNA using Taqman probes,
according to the manufacturer’s instructions, on an Applied
Biosystems 7500 real-time PCR system. Each target assay was
performed in triplicate and normalized to glyceraldehyde-3-
phosphate dehydrogenase.
Ubiquitin precipitation
To detect His6–ubiquitin-conjugated proteins, cell lysates were
prepared in 8 M urea lysis buffer (300 mM NaCl, 0.5% Nonidet
P40, 50 mM NaPO4, 50 mM Tris/HCl, pH 8.0, and 1 mM PMSF)
followed by sonication (25 pulses at output control 2.5, 75%
duty cycle), normalized for protein content, and incubated with
Ni-NTA–agarose beads for 2 h at 4 ◦C. Agarose beads were
recovered by centrifugation at 500 g for 1 min and washed in
8 M urea lysis buffer, and precipitated proteins were eluted by
adding LDS sample buffer (Invitrogen) and heating samples for
10 min at 95 ◦C. Recovered proteins were subsequently separated
by electrophoresis, and examined by immunoblot analysis.
RESULTS
CD30 signalling activates the non-canonical NF-κB pathway and
the degradation of both c-IAP1 and TRAF2
Ligand-mediated activation of many members of the TNFR
superfamily, including CD30, initiates a series of intracellular
signal transduction cascades [41]. The non-canonical NF-κB
signalling pathway is activated by CD30, and is thought to utilize
the signalling intermediate TRAF2, which binds directly to the
cytoplasmictailofCD30[4–7].Inpreviousstudies,wefoundthat
receptor activation rapidly induced the degradation of TRAF2
[10,37], and we proposed a model in which the depletion of
TRAF2 serves both to ‘reset’ the signalling pathway and to
facilitate cross-talk with otherclasses ofreceptorsthat also utilize
TRAF2. Since c-IAP1 is a known TRAF2-binding protein that
has been described recently as a regulator of NF-κB [32,35,42–
44], we sought to determine whether c-IAP1 was also depleted
following receptor activation, along with TRAF2, or whether the
loss of TRAF2 displaced the c-IAP1 protein.
To compare the stability of c-IAP1 before and after receptor
activation, we employed an experimental approach in which
CD30
+ ALCL cells are activated by CD30L, using an adherent
cell line in which CD30L has been stably expressed [10].
ALCL cells were layered on to adherent CD30L-expressing cells
or control cells, and c-IAP1 levels in the ALCL cells were
subsequently examined between 0 and 5 h by immunoblotting.
Interestingly, activation by CD30L resulted in a rapid loss of
c-IAP1 (Figure 1A), concomitant with the loss of TRAF2, which
we described previously using this system as a model to examine
the induction of apoptosis, NF-κB activation and cell-cycle
arrest in different cellular populations [10]. Importantly, CD30
activation also induced the non-canonical NF-κB pathway, as
monitored by analysis of the processing of the p100 NF-κB
subunit to its mature p52 form (Figure 1A, top panel). Under
these conditions, a slight loss of p105 NF-κB was observed,
presumably indicative of processing to p50, although the basal
levels of p50 were found to be relatively high even in the
absenceofCD30activation(Figure1A,middlepanel).Inthelight
of models proposed recently in which c-IAP1 functions to
suppress the levels and activities of factors involved in the non-
canonicalNF-κBpathway,notablyNIK(NF-κB-inducingkinase)
and RIP1 (receptor-interacting protein 1), through mechanisms
thought to involve the E3 ubiquitin ligase activity of c-
IAP1 [32,35,42–44], these ﬁndings suggest a mechanism by
which CD30 signalling activates the non-canonical pathway by
triggering c-IAP proteins for degradation.
Receptor-induced degradation of the TRAF2–c-IAP1 complex
requires the E3 ubiquitin ligase activity of TRAF2, but not
that of c-IAP1
Previous studies found that receptor-induced degradation of
TRAF2 required an intact N-terminal RING domain [37], and
thattheTRAF2RINGfunctionsasanE3ubiquitinligase[45].To
determinewhethertheRINGdomainofTRAF2isrequiredforthe
receptor-mediatedlossofc-IAP1protein,apreviouslyestablished
system was employed in which CD30 signalling is mimicked by
a constitutively active CD28–CD30 chimaera [4]. HEK-293 cells
were transiently transfected with plasmids encoding wild-type
TRAF2 or a RING-deleted dominant-negative TRAF2 protein
(DN-TRAF2 [46]), together with plasmids encoding c-IAP1 and
activated CD30, as detailed in Figure 1(B). Co-expression of
c-IAP1 with TRAF2 resulted in a stabilized form of c-IAP1
(Figure 1B, top panel, compare lanes 3 and 5) (R.A. Csomos
and C.S. Duckett, unpublished work). Consistent with previous
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Figure1 CD30activationinducesthedegradationofbothc-IAP1andTRAF2
(A) Karpas 299 cells were layered on to CHO cells, or CD30L+ CHO cells, for the indicated
periods of time. Cells were recovered, lysed in RIPA buffer and immunoblotted for p100/p52,
p105/p50,c-IAP1andTRAF2asindicated.(B)HEK-293cellsweretransfectedwiththeindicated
combinations of c-IAP1, wild-type TRAF2 and DN-TRAF2, together with a control plasmid or
a constitutively active form of CD30. At 24h after transfection, cell lysates were prepared,
and immunoblot analysis was performed for HA–c-IAP1 and TRAF2. (C) HEK-293 cells were
transfected with plasmids encoding TRAF2, HA–c-IAP1 or HA–c-IAP1 H588A, together with
a control plasmid or a constitutively active form of CD30, as indicated. Cells were harvested
and lysates were analysed by immunoblot as described in (B). Equivalent protein loading was
veriﬁed by immunoblotting for β-actin.
ﬁndings, DN-TRAF2 was not degraded when co-expressed
with active CD30 (Figure 1B, middle panel, lanes 7 and 8).
Interestingly, co-expression of activated CD30 with DN-TRAF2
consistently resulted in the detection of additional TRAF2 and c-
IAP1 species with higher apparent molecular masses (Figure 1B,
compare lanes 6 and 8), suggesting additional post-translational
modiﬁcation of these proteins. Importantly, under the same
conditions and in the same lysates, c-IAP1 also did not degrade
(Figure 1B, top panel, lanes 7 and 8), indicating that the RING
domain of TRAF2 is required for the degradation of c-IAP1 by
CD30.
Sincec-IAP1alsofunctionsasanE3ubiquitinligase,mediated
by a C-terminal RING domain, we examined the involvement
of the RING domain in the degradative process of c-IAP1, as
mediated by receptor activation. The E3 ubiquitin ligase activity
of c-IAP1 was rendered inert by changing a critical histidine
residue at position 588 within the RING domain to alanine
(H588A) [26,47]. HEK-293 cells were subsequently transfected
with plasmids encoding either wild-type c-IAP1 or c-IAP1
H588A and TRAF2 in combination with a control plasmid or
a constitutively signalling form of CD30 (Figure 1C). The E3
ubiquitin ligase-deﬁcient c-IAP1 H588A was readily detected,
and was not stabilized further by the inclusion of TRAF2
(Figure 1C, lane 3). Upon co-expression with the constitutively
active CD30 and subsequent analysis of total detergent-soluble
proteinsbyimmunoblotting,cellularTRAF2levelswereobserved
tobemarkedlyreducedrelativetocellsinwhichthecontrolvector
was included (Figure 1C, compare lanes 2–4 with lanes 6–8),
consistent with previous reports [10,37]. Similarly, c-IAP1 levels
were reduced in the presence of CD30 signalling (Figure 1B,
compare lane 5 with lane 6, and Figure 1C, compare lane 3 with
lane 7), supporting the data with endogenous c-IAP1 described in
Figure 1(A). Interestingly, the c-IAP1 H588A RING mutant was
also degraded (Figure 1C, compare lane 4 with lane 8), indicating
that the E3 ubiquitin ligase activity of c-IAP1 is not required
for the degradation of c-IAP1 or TRAF2, as induced by CD30
signalling. This ﬁnding that the E3 ubiquitin ligase activity of
c-IAP1 is not required for degradation following CD30 activation
contrasts with the requirement of the RING of TRAF2 for CD30-
mediated degradation.
Cytosolic Smac selectively induces autoubiquitination and
proteasome-mediated degradation of c-IAP1, but not TRAF2
The c-IAP antagonist Smac has been shown to regulate the
levels and activity of several IAP proteins following the release
of Smac from mitochondria into the cytosol [48]. Interestingly,
despite its mitochondrial targeting, cytosolic Smac was readily
detectable in ALCL and HL cells (Supplementary Figure
S1 at http://www.BiochemJ.org/bj/420/bj4200083add.htm). To
determine whether the mechanism by which Smac targets c-
IAP1 for degradation was related to CD30-induced degradation
of c-IAP1, we used a mature cytosolic version of Smac that
bypasses mitochondria [49]. Expression of mature Smac resulted
in a decrease in unmodiﬁed c-IAP1 protein and a ladder-like
appearance of higher c-IAP1 moieties (Figure 2A). In contrast,
the expression of mature Smac had no signiﬁcant impact on
TRAF2 expression levels.
Since c-IAP1 harbours E3 ubiquitin ligase activity, a likely
possibility is that Smac might facilitate the autoubiquitination of
c-IAP1. To test this possibility, HEK-293 cells were transfected
with the c-IAP1 H588A mutant in the absence or presence of
Smac. Unlike the pronounced ladder-like appearance of higher
c-IAP1 moieties observed for wild-type c-IAP1 in the presence
of Smac, expression of Smac had no effect on the levels of the
E3 ubiquitin ligase-deﬁcient c-IAP1 (Figure 2A). These ﬁndings
suggest that the mechanism by which Smac regulates c-IAP1
expression is distinct from the mechanism by which c-IAP1 and
TRAF2aretargetedfollowingCD30activation,sinceonlyc-IAP1
protein levels are altered in the presence of Smac, and an intact
RING is necessary for Smac-mediated c-IAP1 degradation.
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Figure 2 Cytosolic Smac triggers the autoubiquitination and degradation
of c-IAP1, but not TRAF2
(A) HEK-293 cells were transiently transfected with HA-tagged c-IAP1 or the c-IAP1 H588A
mutant expression plasmid along with plasmids encoding TRAF2 and mature Smac. At
24 h after transfection, cell lysates were prepared, and immunoblot analysis was performed
for HA–c-IAP1/H588A mutant, Smac and TRAF2. (B) HEK-293 cells were transfected with
combinations of Smac–FLAG, HA–c-IAP1, TRAF2 and His6–ubiquitin (His-Ub). At 24h after
transfection,celllysateswerepreparedin8MureabufferandprecipitatedusingNi-NTA–agarose
beads. The presence of HA–c-IAP1, TRAF2 and Smac–FLAG in the precipitate was determined
by immunoblotting. Equivalent protein loading was veriﬁed in (A)a n d( B) by immunoblotting
for β-actin.
The laddering pattern of c-IAP1 that was observed in the
presence of Smac is highly suggestive of polyubiquitination. To
determine whether Smac could function to induce ubiquitination
of c-IAP1, HEK-293 cells were transfected with a plasmid
encoding His6–ubiquitin and combinations of c-IAP1, TRAF2
and Smac. Cellular lysates were prepared, and ubiquitinated
proteins were precipitated with Ni-NTA–agarose beads. Smac
expression induced the accumulation of high-molecular-mass
ubiquitinatedc-IAP1(Figure2B).Interestingly,theubiquitination
pattern of TRAF2 appeared to be unaffected by Smac (Figure 2B,
middlepanel).SinceSmaccouldinducethepolyubiquitinationof
c-IAP1,butnotTRAF2,thesedatasupportamodelinwhichSmac
functions to speciﬁcally target c-IAP1 for autoubiquitination and
degradation.
Figure 3 c-IAP1 is an inhibitor of the non-canonical NF-κB pathway, and
Smac neutralizes c-IAP1-mediated NF-κB inhibition
HEK-293 cells were transfected with mature Smac–FLAG, HA–c-IAP1 and TRAF2. At 24h
after transfection, cell lysates were prepared, and immunoblot analysis was performed for
p100/p52, HA–c-IAP1, TRAF2 and Smac–FLAG. Equivalent protein loading was conﬁrmed by
immunoblotting for β-actin.
c-IAP1 is an inhibitor of the non-canonical NF-κB pathway, and
Smac neutralizes this inhibition
Distinct targeting of c-IAP1 alone was observed in the presence
of Smac, whereas CD30 activation resulted in the degradation of
both c-IAP1 and TRAF2. Since the loss of c-IAP1 has been
associated with the activation of the non-canonical NF-κB
pathway, we evaluated the effect of Smac on non-canonical NF-
κB activation by examining the processing of the p100 protein
to its transcriptionally active p52 form. Expression of TRAF2
resulted in a signiﬁcant increase in p100 processing to p52,
conﬁrmingpreviousstudiesinwhichTRAF2hasbeenimplicated
in the non-canonical NF-κB pathway (Figure 3, lane 2) [10].
However, co-expression of c-IAP1 with TRAF2 inhibited the
ability of TRAF2 to induce p100 processing (Figure 3, lane
3), consistent with reports that c-IAP1 functions to suppress
the non-canonical pathway by targeting NIK for degradation
[35,44]. Interestingly, expression of mature Smac alone induced
p100 processing (Figure 3, compare lane 1 with lane 6), and
Smac counteracted the inhibitory effects of c-IAP1 on p100
processing (Figure 3, lane 5). In the presence of Smac, the high-
molecular-mass ladder of polyubiquitinated c-IAP1 was again
observed, whereas TRAF2 appeared to be unaffected. Therefore
Smac was found to activate the non-canonical NF-κB signalling
pathway,andthisactivationoccurredconcomitantlywithinduced
autoubiquitination of c-IAP1.
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Figure 4 The IAP antagonist AEG40730 induces the degradation of c-IAP1,
but not TRAF2
(A) HEK-293 cells were transfected with HA–c-IAP1 and TRAF2. At 24h after transfection,
cells were treated with 0, 1, 5, 10 or 25nM AEG40730 or DMSO. At 24h after treatment
with AEG40730, cell lysates were prepared, and immunoblot analysis was performed for
HA–c-IAP1andTRAF2.Equivalentproteinloadingwasconﬁrmedbyimmunoblottingforβ-actin.
(B)HEK-293cellsweretransfectedwithHA–c-IAP1H588A.At24haftertransfection,cellswere
treated with 0, 1, 5, 10 or 25nM AEG40730 or DMSO. At 24h after treatment with AEG40730,
cell lysates were prepared and immunoblotted for HA–c-IAP1 H588A. As a control, c-IAP1
H588A was transfected with mature Smac–FLAG. Equivalent protein loading was veriﬁed by
immunoblotting for β-actin.
A synthetic IAP antagonist selectively targets c-IAP1 for
autoubiquitination
The data presented in Figures 2 and 3 indicate that Smac induces
selective autoubiquitination of c-IAP1, while leaving TRAF2
unaffected, and that this process leads to the activation of the non-
canonical NF-κB pathway by inducing the processing of the
p100 NF-κB subunit. Since a number of synthetic cell-permeable
IAP antagonists have been developed based on the Smac–IAP
interface, we examined the possibility that an IAP antagonist,
AEG40730 [32], would function similarly to mature Smac, by
activatingtheautoubiquitinationofc-IAP1,releasingTRAF2and
triggeringp100processing.Interestingly,AEG40730wascapable
of degrading ectopically expressed c-IAP1 in a similar fashion to
matureSmac,asincreasingconcentrationsofAEG40730resulted
in decreasing levels of c-IAP1 (Figure 4A). Importantly, no
differences in the levels of TRAF2 were observed.
Given the apparent similarities between the effects of mature
Smac and the synthetic IAP antagonist, we sought to test whether
AEG40730 could induce c-IAP1 autoubiquitination by analysis
ofthec-IAP1E3ubiquitinligasemutantH588Ainthepresenceof
increasing doses of AEG40730. Similarly to the results observed
for c-IAP1 H588A in the presence of mature Smac, the RING
mutant of c-IAP1 was insensitive to AEG40730 treatment at any
tested dosage (Figure 4B). These ﬁndings strongly support the
notion that AEG40730 functions analogously to mature Smac in
the ability to stimulate autoubiquitination of c-IAP1.
AEG40730 triggers processing of p100 to p52
Since the IAP antagonist AEG40730 appeared to trigger c-IAP1
autoubiquitination in a similar fashion to mature Smac, we next
investigated the ability of the IAP antagonist to activate the
non-canonical NF-κB pathway through c-IAP1 degradation. To
determine whether AEG40730 was capable of activating the
alternative NF-κB pathway, we examined p100 processing to
p52. HEK-293 (Figure 5A) and Karpas 299 (Figure 5B) cells
were treated for 24 h with increasing doses of AEG40730. As
before,treatmentwithAEG40730inducedthelossofendogenous
c-IAP1, whereas endogenous TRAF2 levels were unaffected
(Figure 5). Importantly, treatment with AEG40730 also resulted
in increased processing of p100 to p52, already evident by 6 h
(Figure 5C). Although a slight reduction in TRAF2 levels was
observed at the highest concentrations or longest time-points,
c-IAP1 expression was essentially abrogated within minutes
of AEG40730 addition, and at the lowest concentrations used.
Therefore AEG40730 was capable of selectively promoting the
degradation of c-IAP1, but not TRAF2, and resulted in the
concomitant processing of p100, similar to the results observed
with mature Smac.
Both Smac and the IAP antagonist AEG40730 potentiate
transcription of endogenous NF-κB target genes
The ﬁnding that both Smac and the synthetic IAP antagonist can
induce the processing of p100 suggested that these agents might
also modulate NF-κB-dependent transcription, as induced by a
deﬁned signal from a TNFR superfamily member such as CD30.
To test this possibility, Karpas 299 cells were transfected with a
plasmidencodingmatureSmacorwithanemptycontrolplasmid,
and subsequently stimulated with control CHO or CD30L
+
CHO cells. Following stimulation, RNA was isolated and qRT-
PCR (quantitative real-time PCR) analysis was performed on
a panel of previously described NF-κB-responsive genes [10].
Interestingly, the induction of NF-κB-dependent genes by CD30
was augmented in cells expressing mature Smac (Figure 6A).
Similarly, pre-treatment of Karpas 299 cells with AEG40730
before CD30 activation resulted in an augmentation of NF-κB-
dependent transcription (Figure 6B), almost identical with that
observedfollowingectopicexpressionofmatureSmac.Therefore
both Smac and the IAP antagonist AEG40730 were found to
function indistinguishably in their ability to potentiate NF-κB-
dependent transcription in response to CD30 activation.
Although the ﬁndings shown in Figures 6(A) and 6(B)
demonstrate a potentiation of NF-κB-dependent transcription in
response to an IAP antagonist or overexpression of mature Smac,
itremainedunclearwhetherendogenousSmaccouldplayarolein
NF-κBactivation.Toaddressthisissue,endogenousSmacexpres-
sion was experimentally suppressed using an oligonucleotide-
mediated siRNA approach, and the expression of deﬁned
NF-κB-target genes was subsequently analysed by qRT-PCR
in response to CD30 activation. Interestingly, Karpas 299 cells
with reduced Smac levels demonstrated a signiﬁcant decrease in
NF-κB-responsive genes following CD30 activation, compared
withcellstransfectedwithcontrololigonucleotidesandstimulated
in parallel through CD30L (Figure 6C). Altogether, these data
indicate that Smac plays a role in the expression of NF-κBt a r g e t
genes, consistent with its role in controlling c-IAP1 levels.
DISCUSSION
In the present study, we examined the cellular regulatory
mechanisms for c-IAP1, which has been shown recently to
function as an NF-κB inhibitory factor [32,42–44]. We found
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Figure 5 Rapid degradation of c-IAP1, but not TRAF2, precedes activation
of the non-canonical NF-κB pathway
TheIAPantagonistAEG40730triggerstheprocessingofp100toitsp52form.(A)HEK-293cells
or(B)Karpas299cellsweretreatedwithDMSOor0,1,5,10or25nMAEG40730andincubated
for24h.(C)Karpas299cellsweretreatedfor0–48hwith25nMAEG40730orDMSO.Following
treatment with AEG40730, cell lysates were prepared, and immunoblot analysis was performed
forc-IAP1,TRAF2andp52/p100.Equivalentproteinloadingwasconﬁrmedbyimmunoblotting
for β-actin. n.s., non-speciﬁc.
Figure 6 Smac is a modulator of CD30-mediated signalling and activates
transcription of endogenous NF-κB-dependent genes
(A) Karpas 299 cells were electroporated with an expression plasmid encoding mature
Smac–FLAG, or an empty control plasmid, as indicated. At 24h after transfection, cells were
layered on to CD30L+ CHO cells or control CHO cells for 2 h. Total RNA was extracted and
reverse-transcribed,andcDNAwasanalysedbyqRT-PCRusingTaqmanprobesfortheindicated
NF-κB-dependent genes. (B) Karpas 299 cells were treated with 25nM AEG40730 or DMSO.
At 24h after following treatment, cells were layered on to CD30L+ CHO cells or control CHO
cells for 2h. Total RNA was extracted and reverse-transcribed, and cDNA was analysed by
qRT-PCRusingTaqmanprobesfortheindicatedNF-κB-dependentgenes.(C)Karpas299cells
were electroporated with double-stranded siRNA oligonucleotides targeting Smac (siSmac) or
an irrelevant sequence (siGFP), as indicated. At 48h after transfection, cells were layered on
to CD30L+ CHO cells or control CHO cells, as indicated, for 2h. Total RNA was extracted and
reverse-transcribed,andcDNAwasanalysedbyqRT-PCRusingTaqmanprobesfortheindicated
NF-κB-responsive genes. ICAM, intercellular adhesion molecule; IκBα, inhibitory κB α.
that c-IAP1 can be regulated by two distinct mechanisms
(Figure 7). During CD30 signalling, c-IAP1 is targeted for
degradation through its association with TRAF2 (Figure 1),
consistent with a recent study examining the effects of signalling
through another TRAF-binding TNFR superfamily member,
FN14 [50]. On the other hand, cytosolic Smac selectively induces
the autoubiquitination and proteasomal degradation of c-IAP1,
whereas TRAF2 is unaffected by Smac (Figures 2 and 3). These
constitute two endogenous cellular mechanisms by which c-IAP1
is controlled. Interestingly, a number of earlier reports describe
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Figure 7 Model of the two mechanisms by which the NF-κB regulatory
factor c-IAP1 can be regulated
SmacandIAPantagonistsinducetheselectiveautoubiquitinationanddegradationofc-IAP1.In
the presence of mature Smac, c-IAP1, but not TRAF2, is degraded. Smac promotes processing
of p100 to p52 and augments non-canonical NF-κB signalling. CD30 activation promotes the
degradation of c-IAP1 and TRAF2. Degradation of c-IAP1 and TRAF2 does not require the E3
ubiquitinligaseactivityofc-IAP1,butdoesrequirestheRINGdomaininTRAF2.CD30signalling
results in the induction of NF-κB through processing of p100 to the active p52 subunit.
the autoubiquitination and degradation of c-IAP proteins after
treatment with IAP antagonists [35,44,48]. The present study
indicates that endogenous Smac plays a similar role and places
thisfactorintheregulationofNF-κBsignallingthroughitseffects
on c-IAP1. In addition, the present study provides functional
evidence in support of the original biochemical screen where
c-IAP proteins were found to associate with TNFR2 [21].
The enhanced expression of CD30 in several forms of
leukaemia and lymphoma suggest that CD30 signalling is
probably involved in the pathogenesis of these tumours [8,9].
Previous studies have described CD30 as an activator of NF-
κB signalling and showed that CD30 induces the degradation of
TRAF2 [10,37]. However, the signiﬁcance of TRAF2 depletion
on NF-κB activation remained unclear. In the present study, we
show that CD30 activation results in the degradation of not only
TRAF2, but also c-IAP1 (Figure 1). Interestingly, the degrada-
tionofTRAF2wasshownpreviouslytorequiretheRINGdomain
of TRAF2 [37], whereas the ﬁndings shown in Figure 1(B)
indicatethattheE3ubiquitinligaseactivityoftheRINGdomainin
c-IAP1 is not required for CD30-mediated degradation. Although
the exact downstream targets of c-IAP1 remain unclear, c-IAP1
has been reported to function as an E3 ubiquitin ligase for NIK,
RIP1 and NEMO (NF-κB essential modulator) and to function
as an inhibitor of NF-κB activation [32,35,42–44,51]. In this
context, receptor-mediated degradation of c-IAP1 is expected to
facilitate NF-κB activation. These data also provide support for
the rationale of targeting c-IAP proteins to promote cell death
through the activation of an autocrine TNF-dependent pathway.
Since several immunotherapeutic approaches are being tested for
CD30
+ malignancies,thetargetingofIAPproteinsincombination
with CD30 might be especially effective.
The classical role described for IAP proteins was to protect
against cell death. Although XIAP has been shown to bind to
and inhibit caspases, the c-IAP proteins do not inhibit caspase
activity. This suggests a non-apoptotic role for the c-IAP1–Smac
interaction. Indeed, earlier reports have described a cytosolic
localization of Smac in non-apoptotic cells. Deng et al. [33]
reportedtheselectivereleaseofSmacfrommitochondriaincolon
carcinoma cells following TNF treatment, and others reported the
existence of an exclusively cytoplasmic variant of Smac, which is
thoughttobegeneratedbyalternativesplicingoftheSmacmRNA
transcript [34]. After observing Smac in the cytosol of healthy
ALCLandHLcells(SupplementaryFigureS1),weexaminedthe
regulation of c-IAP1 by mature Smac or an IAP antagonist. We
found that c-IAP1 underwent autoubiquitination in the presence
of mature Smac or the IAP antagonist (Figures 2, 4 and 5),
supporting previous studies [31]. Interestingly, Smac not only
induced autoubiquitination of c-IAP1, but also activated the non-
canonical NF-κB pathway (Figures 3, 5 and 6), as demonstrated
by the ability of mature Smac to promote processing of p100 to
p52 (Figures 3, 5 and 6).
A provocative earlier study revealed the ability of Smac to
be recruited into the lymphotoxin-β receptor signalling complex
[52].SincewefoundthatSmaccausedincreasedp100processing
and existed in the cytosol of healthy cells, we examined whether
Smac would affect CD30-mediated activation of NF-κB. Indeed,
ectopic expression of Smac was found to potentiate transcription
of endogenous NF-κB-responsive genes (Figures 6A and 6B).
Suppression of Smac also resulted in a reduction of NF-κB
induction (Figure 6C). Therefore, by targeting c-IAP proteins
for degradation, Smac can function as a highly versatile molecule
with the ability to regulate not only caspase-mediated apoptosis,
but also caspase-independent signalling pathways including, but
not restricted to, NF-κB activation. In this context, Smac
might work differently to promote cell survival through NF-κB
target genes. It will be of great importance to fully understand
the intracellular cues that serve to trigger the abilities of
Smac and potentially other IBM-containing proteins to function
physiologically to regulate these processes.
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Figure S1 Smac is located in cytosolic and mitochondrial fractions
CytosolicandmitochondrialfractionswerepreparedfromHLcells(L428)andALCLcells(Karpas
299), and the subcellular distribution of Smac was subsequently analysed by immunoblotting.
Thequalityandintegrityofthemitochondrialandcytosolicfractionswereconﬁrmedbyreprobing
with an antibody directed against cytochrome oxidase subunit IV (COX IV).
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